Literature DB >> 22266486

Accuracy of diagnostic antibody tests for coeliac disease in children: summary of an evidence report.

Klaus Giersiepen1, Monika Lelgemann, Nina Stuhldreher, Luca Ronfani, Steffen Husby, Sibylle Koletzko, Ilma R Korponay-Szabó.   

Abstract

OBJECTIVE: The aim of this study was to summarise the evidence from 2004 to September 2009 on the performance of laboratory-based serological and point of care (POC) tests for diagnosing coeliac disease (CD) in children using histology as reference standard. PATIENTS AND METHODS: We searched MEDLINE and EMBASE for studies reporting on children for tests based on IgA and IgG anti-gliadin (AGA), endomysial (EmA), anti-transglutaminase-2 (TG2), and anti-deamidated gliadin peptides (DGP) antibodies or POC tests. For inclusion, histological analysis of duodenal biopsies and sensitivity and specificity for index tests had to be reported. Data were pooled and summary measures calculated for sensitivity, specificity, positive and negative likelihood ratios ("LR+", "LR-"), and diagnostic odds ratios (DOR). In case of elevated statistical heterogeneity, studies reaching 90% sensitivity or specificity were reported.
RESULTS: A total of 2510 articles were reviewed; 16 entered meta-analysis, reporting on 3110 patients (1876 with CD, 1234 without CD). For IgA-EmA, sensitivity was ≥90% in 7/11 studies and pooled specificity 98.2%. For IgA-anti-TG2, 11/15 studies yielded sensitivities ≥90% and 13/15 specificities ≥90%. For IgA-DGP, sensitivity ranged between 80.7% and 95.1% (specificity 86.3%-93.1%); for IgG-DGP between 80.1% and 98.6% (specificity 86.0-96.9%). IgA-EmA had the highest pooled DOR (554) and LR+ (31.8) for a laboratory test, followed by IgA-anti-TG2, IgG-DGP, IgA-DGP and IgA-AGA. POC tests showed a pooled sensitivity of 96.4% for IgA-TG2 (specificity 97.7%).
CONCLUSIONS: IgA-EmA and IgA-anti-TG2 tests appear highly accurate to diagnose CD. IgG-anti-DGP tests may help in excluding CD. IgA-AGA and IgA-DGP tests show inferior accuracy. POC tests may achieve high accuracy in the hands of experienced readers, but IgA-anti-TG2/EmA were superior.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266486     DOI: 10.1097/MPG.0b013e318216f2e5

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  58 in total

1.  Gluten-free diet in obese patients with celiac disease: an enemy of the bariatric surgeon?

Authors:  Nicola de'Angelis; Maria Clotilde Carra; Francesca Vincenzi
Journal:  Obes Surg       Date:  2012-06       Impact factor: 4.129

Review 2.  Recent Advances in Celiac Disease.

Authors:  Simon Murch
Journal:  Indian J Pediatr       Date:  2016-06-08       Impact factor: 1.967

3.  Distal duodenum versus duodenal bulb: intraepithelial lymphocytes have something to say in celiac disease diagnosis.

Authors:  Ana De Andrés; Cristina Camarero; Garbiñe Roy
Journal:  Dig Dis Sci       Date:  2014-11-04       Impact factor: 3.199

Review 4.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

5.  Intestinal anti-tissue transglutaminase antibodies in potential coeliac disease.

Authors:  A Tosco; R Aitoro; R Auricchio; D Ponticelli; E Miele; F Paparo; L Greco; R Troncone; M Maglio
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

6.  Diagnosis of coeliac disease in children in primary care and clinical implications.

Authors:  Simon Murch; Richard Stevens; Sarah Sleet
Journal:  Br J Gen Pract       Date:  2014-08       Impact factor: 5.386

7.  Evaluation of the ESPGHAN Celiac Guidelines in a North American Pediatric Population.

Authors:  Dominica Gidrewicz; Kathryn Potter; Cynthia L Trevenen; Martha Lyon; J Decker Butzner
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

8.  High-titre circulating tissue transglutaminase-2 antibodies predict small bowel villous atrophy, but decision cut-off limits must be locally validated.

Authors:  L Beltran; M Koenig; W Egner; M Howard; A Butt; M R Austin; D Patel; R R Sanderson; S Goubet; F Saleh; J Lavender; E Stainer; M D Tarzi
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

9.  Intestinal anti-transglutaminase 2 immunoglobulin A deposits in children at risk for coeliac disease (CD): data from the PreventCD study.

Authors:  M Borrelli; M Maglio; I R Korponay-Szabó; V Vass; M L Mearin; C Meijer; H Niv-Drori; C Ribes-Koninckx; M Roca; R Shamir; R Troncone; R Auricchio
Journal:  Clin Exp Immunol       Date:  2017-12-01       Impact factor: 4.330

10.  Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.

Authors:  Abdullah Akbar; Nicole M R McNeil; Marie R Albert; Viviane Ta; Gautam Adhikary; Karine Bourgeois; Richard L Eckert; Jeffrey W Keillor
Journal:  J Med Chem       Date:  2017-09-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.